Clinical drug development is moving away from traditional approaches that rely on rare disease patients to travel long distances to clinical sites and toward a more patient-focused paradigm, one that highlights virtual and decentralized clinical trials (DCT). By bringing trials directly to patients instead of requiring patients to travel to sites, we can alleviate a primary burden of clinical trial participation and democratize clinical trial access. In this white paper, you’ll learn the following key points:

  • How the new research model can increase access to trials, allowing us to bring new therapies to rare disease patients faster.
  • How practical strategies for easing patient participation burdens will aid in transitioning from traditional site-based paradigms to more patient-focused virtual or DCT models.
  • What considerations must be made to select technology that seamlessly integrates clinical trials into patients’ lives.
Decentralized Trials: Reshaping the Rare Disease Landscape

Explore related content and topics